9 Meters Biopharma, Inc.

9 Meters Biopharma is a clinical-stage company pioneering novel therapies for people with rare or debilitating digestive diseases by studying unique GI biology.

[9 Meters Biopharma, Inc. @9metersbio]

In case you missed the recent news.
Links
https://t.co/qHZGYA4C4a
and
https://t.co/bEvboIPpC0

[9 Meters Biopharma, Inc. @9metersbio]

On April 7, 2023, the World Health Organization (WHO) will mark its 75th anniversary, along with its 194 Member States and other partners, by calling for a renewed drive for health equity.”
To learn more about the WHO please visit: https://t.co/Eoj8AVV0Og]

[9 Meters Biopharma, Inc. @9metersbio]

9 Meters Biopharma Provides Business Update and Reports Financial Results for Fourth Quarter and Full Year 2022
https://t.co/tbR7qOXzGf

[9 Meters Biopharma, Inc. @9metersbio]

9 Meters Biopharma to present at the Oppenheimer 33rd Annual Healthcare Conference

Updated Presentation Date/Time:
Wednesday, March 15 at 10:00 AM ET

https://t.co/0gjC4edTnn

[9 Meters Biopharma, Inc. @9metersbio]

9 Meters Biopharma to Present at the Oppenheimer 33rd Annual Healthcare Conference

John Temperato, President and Chief Executive Officer of 9 Meters, is scheduled to present.
Date: Monday, March 13, 2023
Time: 3:20 PM ET
Webcast link:
https://t.co/EXnkDcK4PT

[9 Meters Biopharma, Inc. @9metersbio]

You're Not Alone. If you or a family member are struggling with Short Bowel Syndrome here are some organizations that can help...
#9metersbiopharma

[9 Meters Biopharma, Inc. @9metersbio]

Learn more about Short Bowel Syndrome.

Check out the National Organization for Rare Disorders' (NORD) video library for an animated introduction of SBS: https://t.co/q5bT95l6li.

#9metersbio #sbs

[9 Meters Biopharma, Inc. @9metersbio]

Wishing everyone a happy and healthy #HolidaySeason! We’re looking forward to the new year ahead and continuing our mission to help patients with rare and debilitating digestive disorders.

[9 Meters Biopharma, Inc. @9metersbio]

Our drug candidate for #ShortBowel syndrome (SBS) is designed to counteract the low levels of the hormone GLP-1 seen in SBS. Restoring GLP-1 may slow gut motility & improve intestinal absorption of nutrients and water. Learn more: https://t.co/u87CUnPwZ7

[9 Meters Biopharma, Inc. @9metersbio]

#ICYMI, we announced the design of our Phase 3 study evaluating our drug candidate for #ShortBowel syndrome (SBS). Our team is looking forward to moving one step closer to potentially providing SBS patients with a new treatment option: https://t.co/wIoQOVtdP3

[9 Meters Biopharma, Inc. @9metersbio]

We’re developing a potential #microbiome modulator that was found to be effective alone or when combined with #ImmuneCheckpointInhibitors in a pre-clinical study for spontaneous aggressive skin melanoma. Learn more about our pipeline of candidates: https://t.co/u87CUo78nH

[9 Meters Biopharma, Inc. @9metersbio]

#DYK the average GI tract is ~9 meters? Within those 9 meters, the GI tract has multiple biologic functions that can be harnessed to fight disease. We’re putting the power of gut biology to work to address multiple digestive disease. Learn more: https://t.co/kDwChYETWh

[9 Meters Biopharma, Inc. @9metersbio]

We announced the design of our Phase 3 #ClinicalTrial, VIBRANT 2, to evaluate the efficacy, safety and tolerability of our GLP-1 receptor agonist for adults with #ShortBowel syndrome (SBS). Read the press release for more details: https://t.co/wIoQOVtdP3

[9 Meters Biopharma, Inc. @9metersbio]

We are incredibly thankful for our team at 9 Meters who work hard every day to develop therapeutics for people with rare or debilitating digestive diseases.

[9 Meters Biopharma, Inc. @9metersbio]

Our drug candidate for #ShortBowel syndrome is intended to replace missing GLP-1, a hormone that prevents the #GI tract from moving rapidly, thus normalizing GI transit time and improving intestinal absorption of nutrients and water. Learn more here: https://t.co/u87CUo78nH

[9 Meters Biopharma, Inc. @9metersbio]

$NMTR has announced a continued preclinical collaboration agreement w/ renowned cancer center @GustaveRoussy using our microbiome modulator candidate to study the relationship between intestinal microbiome composition & responses to cancer treatments: https://t.co/N8wNsqxGI6

[9 Meters Biopharma, Inc. @9metersbio]

#DYK #ShortBowelSyndrome (SBS) is a rare syndrome related to poor absorption of nutrients resulting from a significant resection of the small intestine? Learn more about SBS & 9 Meters’ drug candidate in development to treat patients with this disorder: https://t.co/u87CUo78nH

[9 Meters Biopharma, Inc. @9metersbio]

Today we announced a business update and reported financial results for the third quarter of 2022. Read our full press release here: https://t.co/6kLvU9OEmo $NMTR

[9 Meters Biopharma, Inc. @9metersbio]

Recent preclinical data suggest that anti-GIP monoclonal antibodies can reduce body weight without suppressing food intake in mice. We’re developing a humanized anti-GIP monoclonal antibody for the treatment of targeted obesity disorders. Learn more: https://t.co/h2iowgUWuj

[9 Meters Biopharma, Inc. @9metersbio]

Levels of GLP -1, a hormone that slows food’s movement through the GI tract for healthy digestion, can be too low in people with short bowel syndrome (SBS)--leading to poor nutrient absorption. Our Phase 2 drug is intended to offset missing GLP-1 in SBS: https://t.co/u87CUo78nH